共查询到20条相似文献,搜索用时 15 毫秒
1.
《European journal of cancer (Oxford, England : 1990)》2015,51(2):233-240
BackgroundThe national confidential enquiry into patient outcomes and death (NCEPOD) set important benchmarks in assessing the quality of care received by patients dying within 30 days of systemic anticancer therapy (SACT). Monthly morbidity and mortality audits conducted to recommendations in the NCEPOD were commenced at the Christie NHS Foundation Trust in 2009, specifically to assess and improve patient outcomes.MethodsWe evaluated the outcomes of patients who died within 30 days of SACT over a 4 year period 2009–2013. We collated audit findings to determine the number of treatment related deaths, clinical characteristics of patients, causes of death and quality of care received. We examined the benefit of the audit in decreasing 30 day mortality during the 4 years and considered factors that may be associated with an increased risk of SACT related death.ResultsA total of 31,183 patients were treated at the Christie from 2009 to 2013. Of these 4% died within 30 days of SACT. Death was treatment related in 11%. The decision to treat with SACT was appropriate in 87% of but there was room for improvement in care in 24%. Mortality decreased over the 4 years. Possible factors associated with 30 day mortality post SACT included performance status ⩾2, presence of comorbidities, treatment type and treatment setting.ConclusionsWe demonstrated that our audit process is feasible and robust. Further areas of research to determine predictive scores for patient treatment selection and improve outcomes were highlighted and are ongoing. 相似文献
2.
3.
4.
5.
6.
M. S. Kim S. M. Lee H. S. Sung C. H. Won S. Chang M. W. Lee J.‐H. Choi K.‐C. Moon 《Mycoses》2012,55(6):501-506
Deep cutaneous mycoses can cause significant morbidity and mortality, especially in immunocompromised patients. There have been few studies focusing on deep cutaneous mycoses and there are no data from Asian countries. This study aimed to investigate clinical characteristics, underlying predisposing factors, aetiological organisms and outcomes in patients with deep cutaneous mycoses. A retrospective medical record review of patients with deep cutaneous mycoses treated at a tertiary referral centre in Korea from 1999 to 2010. Forty‐one cases of deep cutaneous mycosis were identified (median age: 49). Most patients (32/41) had impaired immunological status, and seven of the remaining nine had a history of physical trauma. Neutropenia and long‐term use of antibiotics were detected in 13 and 12 patients respectively. Nodular skin lesions were the most common type (17/41) and the morphology of the lesions varied. Fungal organisms were identified by culture and histopathology of skin specimens. Candida (16/41) was the most common organism, followed by Aspergillus, Alternaria, Fusarium (4/41 each). Systemic antifungal treatment was successful in 28 patients, while nine patients died from the fungal infection. Our study may lead to improved insights into deep cutaneous mycoses as their incidence is increasing and they vary in different clinical settings. 相似文献
7.
T. Karmiris A. Z. S. Rohatiner S. Love M. Carter R. K. Ganjoo J. Amess A. J. Norton T. A. Lister 《Hematological oncology》1994,12(1):29-39
Over a 24-year period, 137 patients were referred for management of newly diagnosed chronic lymphocytic leukemia. One hundred and nineteen patients have been reviewed in terms of response to therapy and prognostic factors for survival; 18 patients were excluded either because lymph node biopsy was not compatible with the diagnosis of CLL (11 patients), or because the lymphocyte count at presentation was < 5 × 109/1 (seven patients). Patients were staged retrospectively according to both the Rai and Binet Classifications. Forty-eight per cent (57/119) were deemed not to be in need of any treatment at presentation, 36 per cent (43/119) have never received any specific therapy. The majority of patients received chlorambucil alone, at a dose of 10 mg daily given for 6 weeks, followed by a 2-week interval, followed by three, 2-week cycles. The overall response rate (complete + partial remission) was 38 per cent. In terms of survival, there was a trend in favour of patients who responded to treatment in comparison with those who did not but this did not reach statistical significance (P=0.07). Correlation with stage were highly significant, the median survivals for patients with stage A, B and C disease (Binet) were 12.5, 8 and 3.5 years respectively. On univariate analysis, the absolute lymphocyte count at presentation was the most significant prognostic factor for survival, patients presenting with an absolute lymphocyte count above 50 × 109/1 having a less favourable prognosis (P=0.002). However, on multivariate analysis, older age, a low hemoglobin, low platelet count, and the presence of lymphadenopathy and fever at presentation correlated adversely with survival. Overall, 40 patients died as a consequence of CLL or from disease-related causes, 34/40 dying of infection. Twenty-one patients developed second cancers. With a median follow-up of 13 years, these results confirm that the two staging systems can separate patients into prognostic groups, however in practice, there is heterogeneity of outcome within stage. New approaches are urgently needed. 相似文献
8.
Trends of genetic screening in patients with pheochromocytoma and paraganglioma: 15‐year experience in a high‐volume tertiary referral center 下载免费PDF全文
Ammar Asban MD Wouter P. Kluijfhout MSc Frederick T. Drake MD Toni Beninato MD Elizabeth Wang MD Kate Chomsky‐Higgins MD Wen T. Shen MD MA Jessica E. Gosnell MD Insoo Suh MD Quan‐Yang Duh MD 《Journal of surgical oncology》2018,117(6):1217-1222
9.
10.
11.
Three‐year experience with interventional neuroradiology for management of cerebral aneurysms at a single Australian centre 下载免费PDF全文
Aden McLaughlin Hal Rice Laetitia de Viliers Teresa Withers David Pearson Moira Arnell Kerin Walters Sarah Czuchwicki Andrew Bulmer James Winearls 《Journal of Medical Imaging and Radiation Oncology》2018,62(1):51-56
12.
Transarterial chemoembolization of unresectable systemic chemotherapy‐refractory liver metastases from colorectal cancer: Long‐term results over a 10‐year period 下载免费PDF全文
Tatjana Gruber‐Rouh Nagy N.N. Naguib Katrin Eichler Hanns Ackermann Stephan Zangos Jörg Trojan Martin Beeres Marc Harth Boris Schulz Nour‐Eldin Nour‐Eldin A. Thomas J. Vogl 《International journal of cancer. Journal international du cancer》2014,134(5):1225-1231
The aims of the study were to evaluate therapeutic efficacy and to determine the prognostic factors for treatment success in patients with liver metastases from colorectal cancer (CRC) treated with transarterial chemoembolization (TACE). A total of 564 patients (mean age, 60.3 years) with liver metastases of CRC were repeatedly treated with TACE. In total, 3,384 TACE procedures were performed (mean, six sessions per patient). The local chemotherapy protocol consisted of mitomycin C alone (43.1%), mitomycin C with gemcitabine (27.1%), mitomycin C with irinotecan (15.6%) or mitomycin C with irinotecan and cisplatin (15.6%). Embolization was performed with lipiodol and starch microspheres. Tumor response was evaluated using magnetic resonance imaging or computed tomography. The change in tumor size was calculated and the response was evaluated according to the RECIST‐Criteria. Survival rates were calculated according to the Kaplan–Meier method. Prognostic factors for patient's survival were evaluated using log‐rank test. Evaluation of local tumor control showed partial response in 16.7%, stable disease in 48.2% and progressive disease in 16.7%. The 1‐year survival rate after chemoembolization was 62%, the 2‐year survival rate was 28% and the 3‐year survival rate was 7%. Median survival from the start of chemoembolization treatment was 14.3 months. The indication (p = 0.001) and initial tumor response (p = 0.015) were statistically significant factors for patient's survival. TACE is a minimally invasive therapy option for controlling local metastases and improving survival time in patients with hepatic metastases from CRC. TN stage, extrahepatic metastases, number of lesions, tumor location within the liver and choice of chemotherapy protocol of TACE are none significant factors for patient's survival. 相似文献
13.
14.
15.
Three‐year cytohistological correlation of salivary gland FNA cytology at a tertiary center with the application of the Milan system for risk stratification 下载免费PDF全文
Manish Rohilla MD Priya Singh MD Arvind Rajwanshi MD FRCPath Nalini Gupta MD DNB Radhika Srinivasan MD PhD Pranab Dey MD FRCPath Rakesh K. Vashishta MD FRCPath 《Cancer cytopathology》2017,125(10):767-775
16.
Limited data are available on temporal and geographic variation of occurrence and antifungal resistance of non‐C. albicans Candida species (non‐CA‐CSP) from the USA. The objective of this study was to evaluate the occurrence and antifungal resistance of 1694 isolates of non‐CA‐CSP collected during the period 2006–2011. Isolates were recovered in 33 hospitals located in four regions: Northcentral, North‐east, South‐east and West and tested using CLSI reference broth microdilution methods. Non‐CA‐CSP represented 55.6% of all Candida. C. glabrata was most predominant (39–42% of non‐CA‐CSP). Infections due to C. glabrata, C. krusei and C. dubliniensis increased over the 6 years. Anidulafungin (3.6%) and caspofungin (5.7%) resistance were prominent among C. glabrata from the North‐east and West regions respectively. Resistance to micafungin was detected in 2.0% and 2.9% of C. glabrata from the West and North‐east regions respectively. Echinocandin resistance was low, except for C. dubliniensis. Azole resistance was most prominent among C. glabrata from the South‐east (13.6% fluconazole R) and the West (18.0%). Cross‐resistance among three tested azoles was observed in C. glabrata from all regions. Whereas differences in species distribution and antifungal R varied across geographic regions, there was little evidence of temporal increase in resistance to azoles or echinocandins in the monitored non‐CA‐CSP. 相似文献
17.
18.
Beatriz L. P. Junqueira MD Bairbre Connolly MB BCh BAO Oussama Abla MD George Tomlinson PhD Joao G. Amaral MD 《Cancer》2010,116(18):4368-4375
BACKGROUND:
The objective of this study was to determine whether severe neutropenia on the day of port‐a‐catheter (PORT) insertion was a risk factor for catheter‐associated infection (CAI) in children with acute lymphoblastic leukemia (ALL).METHODS:
This was a retrospective study of children with ALL who had a PORT insertion between January 2005 and August 2008. Early (≤30 days) and late (>30 days) postprocedure complications were reviewed. The length of follow‐up ranged between 7 months and 42 months.RESULTS:
In total, 192 PORTs were inserted in 179 children. There were 43 CAIs (22%), and the infection rate was 0.35 per 1000 catheter‐days. The CAI rate (15%) in children who had severe neutropenia on the day of the procedure did not differ statistically from the CAI rate (24%) in children who did not have severe neutropenia (P = .137). Conversely, patients with severe neutropenia who had a CAI were more likely to have their PORT removed (P = .019). The most common organisms to cause catheter removal were coagulase‐negative Staphylococcus and Staphylococcus aureus. Patients with high‐risk ALL had a statistically significant higher incidence of late CAI than patients with standard‐risk ALL (P = .012). Age (P = .272), positive blood culture preprocedure (P = 1.0), and dexamethasone use (P = .201) were not risk factors for CAI. Patients who had an early CAI did not have a greater chance of having a late CAI. The catheter infection‐free survival rate at 1 year was 88.6%.CONCLUSIONS:
The current results indicated that severe neutropenia on the day of PORT insertion does not increase the risk of CAI in children with ALL. Cancer 2010. © 2010 American Cancer Society. 相似文献19.
Silva E 《Familial cancer》2008,7(1):91-95
Women with a family history of breast cancer who are diagnosed with breast cancer are often counseled to undergo prophylactic
mastectomy as part of their treatment for breast cancer. The majority of such individuals make these decisions in haste and
without appropriate genetic counseling or testing. Most of them when tested for BRCA or other established mutations find that
they are not mutation carriers. In retrospect, this realization leads many to question the wisdom of their prophylactic surgery
which is often associated with complications and quality of life problems which they never envisioned. We have designed an
algorithm for the management of these patients which minimizes these lifelong problems. 相似文献
20.
《European journal of cancer (Oxford, England : 1990)》2014,50(14):2375-2389
BackgroundThe TACT trial (CRUK/01/001) compared adjuvant sequential FEC-docetaxel (FEC-D) chemotherapy with standard anthracycline-based chemotherapy of similar duration in women with early breast cancer. Results at a median of 5 years suggested no improvement in disease-free survival with FEC-D. Given differing toxicity profiles of the regimens, the impact on quality of life (QL) was explored.MethodsPatients from 44 centres completed standardised QL questionnaires before chemotherapy, after cycles 4 and 8, at 9, 12, 18 and 24 months and at 6 years follow-up. Patient diaries assessed frequency, associated distress and impact on daily activity of 15 treatment related side effects.Findings830 patients (415 FEC-D; 415 controls) contributed assessments during 0–24 months; 362 of whom participated again at 6 years. During chemotherapy, FEC-D impaired global health/QL and depression rates and significantly more QL domains than standard regimens. Novel diary card ratings highlighted significantly more distress and interference with daily activities due to FEC-D side effects compared with standard treatment. In both groups, most QL parameters returned to baseline levels by 2 years and were unchanged at 6 years.InterpretationWithin expected negative effects of chemotherapy on wide ranging QL domains FEC-D patients reported greater toxicity, disruption and distress during treatment with no improvement in disease outcome at 5 years than patients receiving standard anthracycline-based chemotherapy. Findings should inform future patients of relative costs and benefits of adjuvant chemotherapy. 相似文献